ReviewTrends in microbiology2013
Rising to the challenge: new therapies for tuberculosis.
Review in Trends in microbiology, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
31 citing papers in PubMed.
- Population pharmacokinetic and exposure-response study of a novel anti-tuberculosis drug to inform its dosage design in phase III clinical trial.European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences · 2025Trial
- Significant Effects of Oral Phenylbutyrate and Vitamin D3 Adjunctive Therapy in Pulmonary Tuberculosis: A Randomized Controlled Trial.PloS one · 2015Trial
- Inflammasome activation dictates the efficacy of antimycobacterial activity of frontline TB drugs.PLoS pathogens · 2026Article
- From Repurposing to Refinement: Optimizing Levofloxacin for Treatment of Multidrug-Resistant Tuberculosis.American journal of respiratory and critical care medicine · 2025Article
- Assessment of tuberculosis drug efficacy using preclinical animal models and in vitro predictive techniques.npj antimicrobials and resistance · 2024Article
- Novel Prodrug Strategies for the Treatment of Tuberculosis.Chemistry, an Asian journal · 2024Review
- Impact of bedaquiline regimen on the treatment success rates of multidrug-resistant tuberculosis patients in Egypt.Scientific reports · 2024Article
- Transposon mutagenesis ineLife · 2022Article
- Pretomanid for tuberculosis treatment: an update for clinical purposes.Current research in pharmacology and drug discovery · 2022Review
- Revisiting Anti-tuberculosis Therapeutic Strategies That Target the Peptidoglycan Structure and Synthesis.Frontiers in microbiology · 2019Review
- Antimycobacterial activity of an anthracycline produced by an endophyte isolated from Amphipterygium adstringens.Molecular biology reports · 2018Article
- Treating tuberculosis with high doses of anti-TB drugs: mechanisms and outcomes.Annals of clinical microbiology and antimicrobials · 2017Review
- Learning from the past for TB drug discovery in the future.Drug discovery today · 2017Review
- Paradoxical Hypersusceptibility of Drug-resistant Mycobacteriumtuberculosis to β-lactam Antibiotics.EBioMedicine · 2016Article
- Advances in Drug Discovery and Development for Pediatric Tuberculosis.Mini reviews in medicinal chemistry · 2016Review
- Syntheses and Biological Evaluations of Highly Functionalized Hydroxamate Containing andMedChemComm · 2016Article
- A Web-Based Platform for Designing Vaccines against Existing and Emerging Strains of Mycobacterium tuberculosis.PloS one · 2016Article
- Syntheses and evaluation of substituted aromatic hydroxamates and hydroxamic acids that target Mycobacterium tuberculosis.Bioorganic & medicinal chemistry letters · 2015Article
- Short, Synthetic Cationic Peptides Have Antibacterial Activity against Mycobacterium smegmatis by Forming Pores in Membrane and Synergizing with Antibiotics.Antibiotics (Basel, Switzerland) · 2015Article
- Myeloid Growth Factors Promote Resistance to Mycobacterial Infection by Curtailing Granuloma Necrosis through Macrophage Replenishment.Cell host & microbe · 2015Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
The standard treatment for tuberculosis (TB) is lengthy, complex, and significantly toxic. Drug development for TB has stagnated for decades, but in recent years renewed commitment and coordinated research has generated a modest pipeline of new drugs that hold the potential to make treatment more effective, shorter, less complex, and less toxic in the near future. With a particular focus on bedaquiline (TMC207), the first anti-TB drug of a novel class to be approved by the US Food and Drug Administration (FDA) in 40 years, this review summarizes the recent evidence behind new developments in TB treatment. Novel drug classes, repurposed drugs, and host-directed therapies are reviewed. In parallel to these exciting developments in drug discovery, we propose that it is crucial to develop more rapid and comprehensive diagnostics that will allow the timely selection of the best regimen for individual patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.